Table 1.
The Cox regression analysis of the association between clinicopathological factors (including risk scores) and the disease-free survival of BRCA patients.
| Variables | Group | Patients (N) | Univariate analysis | Patients (N) | Multivariate analysis | ||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||||
| TCGA | |||||||
| Risk score | Low/high | 475/475 | 4.18 (2.50-6.97) | 4.37E − 08 | 418/411 | 4.40 (2.31-8.39) | 6.62E − 06 |
| Age | ≤50/>50 | 290/660 | 0.67 (0.43-1.03) | 6.59E − 02 | 251/578 | 0.66 (0.39-1.11) | 1.14E − 01 |
| Pathologic stage | I-II/III-IV | 723/216 | 3.34 (2.15-5.19) | 8.81E − 08 | 645/184 | 4.28 (2.49-7.34) | 1.31E − 07 |
| ER status | N/P | 214/697 | 0.49 (0.31-0.77) | 1.78E − 03 | 191/638 | 1.35 (0.32-5.61) | 6.82E − 01 |
| PR status | N/P | 304/604 | 0.46 (0.30-0.71) | 5.34E − 04 | 274/555 | 0.56 (0.26-1.19) | 1.29E − 01 |
| HER2 status | N/P | 680/160 | 0.93 (0.47-1.82) | 8.22E − 01 | 671/158 | 0.72 (0.30-1.69) | 4.47E − 01 |
| Triple negative | No/yes | 804/146 | 1.62 (0.97-2.71) | 6.39E − 02 | 685/144 | 1.89 (0.43-8.35) | 4.02E − 01 |
| GSE20685 | |||||||
| Risk score | Low/high | 164/163 | 2.41 (1.58-3.68) | 4.16E − 05 | 164/158 | 2.22 (1.43-3.43) | 3.55E − 04 |
| Age | ≤50/>50 | 209/118 | 0.74 (0.48-1.14) | 1.71E − 01 | 206/116 | 0.79 (0.49-1.27) | 3.36E − 01 |
| T stage | I-II/III-IV | 101/188 | 1.93 (1.50-2.49) | 3.27E − 07 | 100/186 | 1.22 (0.86-1.74) | 2.57E − 01 |
| N stage | N0/N1-3 | 137/190 | 3.73 (2.26-6.15) | 2.49E − 07 | 135/187 | 3.46 (1.99-6.01) | 1.06E − 05 |
| M stage | M0/M1 | 319/8 | 21.96 (10.49-45.99) | 2.59E − 16 | 315/7 | 5.78 (2.02-16.58) | 1.10E − 03 |
| Adjacent CT | No/yes | 54/268 | 2.07 (1.07-3.99) | 3.05E − 02 | 54/268 | 1.34 (0.65-2.76) | 4.26E − 01 |
| GSE21653 | |||||||
| Risk score | Low/high | 126/126 | 2.83 (1.77-4.53) | 1.32E − 05 | 115/113 | 3.04 (1.80-5.11) | 3.00E − 05 |
| Age | ≤50/>50 | 92/160 | 1.14 (0.72-1.79) | 5.83E − 01 | 81/147 | 1.31 (0.79-2.17) | 2.95E − 01 |
| T stage | I-II/III-IV | 178/66 | 1.70 (1.06-2.73) | 2.75E − 02 | 164/64 | 1.20 (0.72-2.01) | 4.87E − 01 |
| N stage | N0/N1-3 | 116/133 | 1.54 (0.98-2.40) | 5.84E − 02 | 105/123 | 1.61 (0.97-2.69) | 6.81E − 02 |
| ER status | N/P | 110/140 | 0.66 (0.43-1.02) | 5.94E − 02 | 100/128 | 0.46 (0.17-1.26) | 1.31E − 01 |
| PR status | N/P | 124/126 | 0.84 (0.55-1.30) | 4.35E − 01 | 114/114 | 1.43 (0.60-3.38) | 4.15E − 01 |
| HER2 status | N/P | 207/26 | 1.59 (0.84-3.03) | 1.58E − 01 | 204/24 | 1.09 (0.42-2.85) | 8.60E − 01 |
| Triple negative | No/yes | 160/85 | 1.19 (0.74-1.89) | 4.73E − 01 | 145/83 | 0.88 (0.26-2.90) | 8.29E − 01 |
| GSE42568 | |||||||
| Risk score | Low/high | 52/52 | 3.68 (1.97-6.88) | 4.55E − 05 | 51/50 | 4.18 (2.13-8.17) | 2.99E − 05 |
| Age | ≤50/>50 | 27/77 | 0.66 (0.36-1.21) | 1.79E − 01 | 25/76 | 0.72 (0.36-1.46) | 3.63E − 01 |
| N stage | N0/N1-3 | 45/59 | 4.35 (2.16-8.76) | 3.88E − 05 | 44/57 | 4.72 (2.24-9.95) | 4.53E − 05 |
| ER status | N/P | 34/67 | 0.44 (0.24-0.79) | 6.35E − 03 | 34/67 | 0.40 (0.21-0.77) | 5.77E − 03 |
HR: hazard ratio; CI: confidence interval; ER: estrogen receptor; PR: progesterone receptor; HER2/erbb2: epidermal growth factor receptor 2; Adjacent CT: adjacent chemotherapy; N: negative; P: positive.